iZO Promo Review
Fictional brands · Sample data as of 12 Oct 2026
Item search
6Approved

P-103 Pharmacy Leave-Behind

P-103 · Pharmacy leave-behind · Brand X · [Therapy area]

Where is it now

  1. Brief
  2. Agency creates
  3. Ops checks
  4. Submit to review
  5. Review meeting
  6. Reconcile feedback
  7. Approve and release

Where the status came from

Source system
Veeva Vault PromoMats
Raw status
"Approved for Distribution"
Normalized
"Approved for Distribution" Approved

Turnaround clock

Stopped 9 days
Submitted 9 Sept 2026 → approved 18 Sept 2026

Iterations (2)

VersionDateOutcome
v13 Sept 2026Changes requested
v213 Sept 2026Approved — final

History

  1. 19 Sept 2026 — Released to channelMarketing ops
  2. 18 Sept 2026 — Final approval recorded (raw status "Approved for Distribution") — clock stopsVeeva Vault PromoMats
  3. 17 Sept 2026 — Review meeting — Medical, Regulatory, Legal agreeMLR reviewers
  4. 13 Sept 2026 — Feedback reconciled, v2 resubmittedAgency
  5. 11 Sept 2026 — Review meeting — changes requested on v1MLR reviewers
  6. 9 Sept 2026 — Submitted to MLR review, v1 (Veeva Vault PromoMats) — clock startsVeeva Vault PromoMats
  7. 7 Sept 2026 — Ops pre-check passedOps
  8. 3 Sept 2026 — Agency draft v1Agency
  9. 1 Sept 2026 — Brief receivedMarketing ops

Claims in this piece (4)

  • C-001 [Outcome A] reached by Week 12 in [Study 1]Existing
  • C-003 Once-daily oral dosing, with or without foodExisting
  • C-008 No dose adjustment needed for [population]Modified
  • C-011 [Outcome F] in patients previously treated with [drug class]Prior approval expired